Advances in ALS: New Targets, Trials, and Care Strategies

Update: 2025-10-27

Description

Merit Cudkowicz, MD, Julieanne Professor of Neurology, Harvard Medical School, Boston, MA, discusses the evolving landscape of treatment for ALS, including FDA-approved disease-modifying therapies, the importance of genetic testing, the emergence of gene therapies, and the promising clinical trial pipeline targeting genetic and sporadic forms of ALS.